Quoin Pharmaceuticals Secures Second Rare Pediatric Disease Designation for QRX003 — Quoin Pharmaceuticals, Ltd.

Event summary

FDA granted Rare Pediatric Disease (RPD) Designation to QRX003 for Peeling Skin Syndrome (PSS), a second RPD designation for the drug after Netherton Syndrome.
Quoin Pharmaceuticals may receive a Priority Review Voucher (PRV) if QRX003's NDA is approved, potentially worth over $300 million.
Phase 2 study for PSS expected to begin in the second half of 2026, enrolling up to 12 pediatric and adult patients in the U.S. and Europe.
No approved treatments currently exist for Peeling Skin Syndrome.

The big picture

Quoin Pharmaceuticals' second RPD designation for QRX003 underscores the growing focus on rare pediatric diseases within the biotech sector. The potential PRV, valued at over $300 million, highlights the strategic importance of developing treatments for underserved patient populations. This designation also positions Quoin to potentially expand its pipeline across multiple rare and orphan indications, aligning with broader industry trends toward specialized therapeutic solutions.

What we're watching

Regulatory Strategy: How Quoin Pharmaceuticals will leverage the second RPD designation to accelerate regulatory approvals and maximize the value of potential PRVs.
Clinical Execution: The pace at which the Phase 2 study for PSS will enroll patients and generate data, given the rarity of the condition.
Commercial Potential: Whether the PRV and other designations will attract strategic partnerships or buyers for Quoin Pharmaceuticals.